VIVS VivoSim Labs Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: VIVS

Price (delayed)

$1.13

Market cap

$2.95M

P/E Ratio

0.65

Dividend/share

N/A

EPS

$1.75

Enterprise value

-$672,003

?
Relative Growth: Rel. Growth: 51
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 79
Relative Profitability: Rel. Profitability: 41

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are ...

Highlights
The EPS has soared by 117% year-on-year
The net income has surged by 90% year-on-year and by 38% since the previous quarter
The equity has declined by 37% since the previous quarter
VIVS's quick ratio is down by 31% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.organovo.com
Peers: ISRG UTHR MMM DDD

Key stats

What are the main financial stats of VIVS

VIVS stock price

How has the VivoSim Labs stock price performed over time
Intraday
0%
1 week
-3.42%
1 month
-16.91%
1 year
-23.13%
YTD
-37.57%
QTD
-20.98%

Financial performance

How have VivoSim Labs's revenue and profit performed over time
Revenue
$142,000
Gross profit
$142,000
Operating income
-$11.45M
Net income
-$1.23M
Gross margin
100%
Net margin
-864.1%
VIVS's net margin has surged by 91% year-on-year and by 39% since the previous quarter
The net income has surged by 90% year-on-year and by 38% since the previous quarter
The operating margin is up by 22% year-on-year and by 7% since the previous quarter
VIVS's gross profit is up by 21% year-on-year and by 2.9% since the previous quarter

Price vs fundamentals

How does VIVS's price correlate with its fundamentals

Growth

What is VivoSim Labs's growth rate over time

Valuation

What is VivoSim Labs stock price valuation
P/E
0.65
P/B
0.66
P/S
20.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.73
The EPS has soared by 117% year-on-year
The stock's price to book (P/B) is 70% less than its 5-year quarterly average of 2.2 and 6% less than its last 4 quarters average of 0.7
The equity has declined by 37% since the previous quarter
The P/S is 55% below the 5-year quarterly average of 46.2 and 39% below the last 4 quarters average of 34.1
The revenue has grown by 16% YoY

Efficiency

How efficient is VivoSim Labs business performance
The ROE has soared by 95% YoY and by 46% from the previous quarter
VIVS's return on assets has surged by 94% year-on-year and by 43% since the previous quarter
The ROS has soared by 92% year-on-year and by 39% since the previous quarter
VIVS's return on invested capital has surged by 80% year-on-year and by 38% since the previous quarter

Dividends

What is VIVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIVS.

Financial health

How did VivoSim Labs financials performed over time
The total assets is 176% greater than the total liabilities
The total assets has surged by 81% year-on-year but it has declined by 28% since the previous quarter
VIVS's quick ratio is down by 31% from the previous quarter
VIVS's debt is 82% smaller than its equity
The debt to equity has plunged by 95% YoY but it has grown by 20% from the previous quarter
VIVS's debt is down by 38% year-on-year and by 23% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.